Cambrex (CBM) stock price, revenue and financials

+0.08 (+0.14%)

$1.9 B

CBM Mkt cap, 15-Oct-2018

$285.9 M

Cambrex Revenue Q2, 2018

Cambrex Gross profit (Q2, 2018)108.4 M

Cambrex Gross profit margin (Q2, 2018), %37.9%

Cambrex Net income (Q2, 2018)64.5 M

Cambrex EBIT (Q2, 2018)75 M

Cambrex Cash, 30-Jun-2018171.3 M

Annual

USD	FY, 2016
Revenue	489.2m
Cost of goods sold	286.4m
Gross profit	202.8m
Gross profit Margin, %	41%
R&D expense	14.3m
General and administrative expense	60.4m
Operating expense total	74.7m
EBIT	128.4m
EBIT margin, %	26%
Interest expense	717.0k
Pre tax profit	127.5m
Net Income	81.7m

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q3, 2017	Q1, 2018	Q2, 2018
Revenue	97.3m	80.6m	77.7m	106.0m	91.7m	93.4m	118.2m	99.3m	103.1m	112.0m	138.9m	285.9m
Cost of goods sold	64.5m	52.9m	48.4m	60.7m	57.3m	55.8m	70.1m	61.8m	58.2m	65.7m	90.2m	177.5m
Gross profit	32.9m	27.7m	29.3m	45.3m	34.4m	37.6m	48.1m	37.5m	44.9m	46.3m	48.7m	108.4m
Gross profit Margin, %	34%	34%	38%	43%	38%	40%	41%	38%	44%	41%	35%	38%
R&D expense	3.6m	3.8m	2.7m	2.7m	3.7m	3.5m	4.1m	3.2m	3.9m		3.6m	7.8m
General and administrative expense	14.6m	12.5m	13.8m	14.1m	14.0m	14.0m	13.6m	15.0m	15.8m		16.9m	32.9m
Operating expense total	18.2m	16.4m	16.4m	16.8m	17.7m	17.5m	17.7m	18.1m	19.6m	21.8m	20.5m	40.6m
EBIT	15.2m	12.0m	12.7m	29.2m	18.0m	21.4m	30.8m	19.5m	27.2m	25.1m	30.4m	75.0m
EBIT margin, %	16%	15%	16%	28%	20%	23%	26%	20%	26%	22%	22%	26%
Interest expense	543.0k	570.0k	476.0k	474.0k	517.0k			366.0k			82.0k	99.0k
Pre tax profit	10.4m	11.4m	12.1m	28.9m	17.2m	21.4m	30.6m	19.2m	26.9m	24.8m	30.0m	79.6m
Income tax expense			3.8m			6.6m	9.8m	5.4m	5.8m	7.5m	5.8m	14.5m
Net Income	20.6m	29.4m	8.0m	27.7m	39.4m	14.6m	35.1m	44.3m	19.9m	17.3m	24.1m	64.5m

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	22.7m	45.5m	44.0m	74.1m
Accounts Receivable	12.9m	10.6m	7.3m	6.7m
Inventories	5.6m	8.7m	7.2m	123.2m
Current Assets	202.6m	227.6m	259.3m	322.7m
PP&E	172.0m	163.6m	186.5m	217.1m
Goodwill	38.7m	43.9m	32.1m	40.3m
Total Assets	458.0m	487.1m	505.5m	611.9m
Accounts Payable	29.1m	43.7m	39.3m	42.9m
Current Liabilities	97.3m	98.8m	129.8m	95.5m
Long-term debt	79.3m	60.0m
Total Liabilities				206.4m
Additional Paid-in Capital	109.8m	119.3m	132.0m	153.7m
Retained Earnings	131.2m	188.5m	245.7m	327.4m
Total Equity	210.2m	251.2m	310.8m	405.4m
Financial Leverage	2.2 x	1.9 x	1.6 x	1.5 x

Quarterly

USD	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q3, 2017	Q1, 2018	Q2, 2018
Cash	62.6m	60.2m	85.6m	52.5m	90.7m	99.2m	118.4m	187.6m	171.3m
Accounts Receivable	8.1m	7.4m	9.6m	10.8m	7.4m	7.5m	81.8m	55.2m	100.2m
Inventories	127.1m	130.9m	131.6m	140.1m	143.9m	151.5m	5.1m	104.5m	99.6m
Current Assets	253.4m	246.0m	283.8m	279.9m	289.0m	332.8m	378.1m	462.7m	504.2m
PP&E	172.4m	180.6m	203.6m	204.2m	209.2m	223.8m		270.4m	266.1m
Goodwill	41.7m	41.4m	33.2m	32.6m	32.7m	40.7m	43.2m	44.4m	42.9m
Total Assets	512.9m	509.7m	544.2m	536.9m	555.1m	627.5m	698.4m	796.2m	830.9m
Accounts Payable	42.1m	52.7m	39.3m	36.6m	36.8m	38.8m	39.9m	43.9m	51.6m
Current Liabilities	108.9m	123.3m	104.5m	80.7m	78.9m	84.9m	84.2m	91.8m	96.4m
Long-term debt	60.0m	30.0m
Total Liabilities							200.5m	203.5m	207.6m
Additional Paid-in Capital	123.8m	126.9m	133.2m	136.8m	141.1m	154.9m	162.1m	170.3m	172.5m
Retained Earnings	216.1m	227.9m	260.3m	280.8m	290.0m	347.2m	389.6m	470.1m	510.5m
Total Equity	272.5m	286.4m	335.1m	353.1m	366.9m	430.5m	497.9m	592.7m	623.3m
Financial Leverage	1.9 x	1.8 x	1.6 x	1.5 x	1.5 x	1.5 x	1.4 x	1.3 x	1.3 x

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Net Income	25.9m	57.3m	57.2m	81.7m
Depreciation and Amortization	22.5m	23.8m	22.1m	24.7m
Inventories	(19.0m)	(9.1m)	(33.0m)	(23.7m)
Accounts Payable	10.1m	12.4m	10.3m	1.8m
Cash From Operating Activities	36.9m	65.0m	83.6m	123.3m
Cash From Investing Activities	(56.6m)	(24.8m)	(60.2m)	(74.0m)
Cash From Financing Activities	18.2m	(14.5m)	(22.7m)	(17.3m)
Free Cash Flow	94.2m	88.3m	146.1m	73.6m

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q3, 2017	Q1, 2018	Q2, 2018
Net Income	20.6m	29.4m	8.0m	27.7m	39.4m	14.6m	35.1m	44.3m	19.9m	17.3m	24.1m	64.5m
Depreciation and Amortization	11.8m	17.9m	5.3m	10.7m	16.3m	5.6m	11.3m	17.7m	7.2m		7.5m	15.0m
Accounts Receivable										81.8m
Inventories	(16.5m)	(22.2m)	(29.0m)	(46.5m)	(52.5m)	(21.0m)	(35.0m)	(40.1m)	(28.2m)	5.1m	(58.0k)	(1.0m)
Accounts Payable	1.4m	8.1m	(2.2m)	2.7m	13.8m	4.0m	(12.4m)	(11.5m)	(10.0m)	39.9m	4.1m	10.2m
Cash From Operating Activities	12.5m	41.4m	35.4m	40.2m	80.0m	89.8m	64.6m	111.8m	36.0m	72.1m	24.5m	17.5m
Cash From Investing Activities	(12.0m)	(20.2m)	(12.0m)	(23.5m)	(37.5m)	(19.8m)	(26.5m)	(37.7m)	(12.2m)	(35.4m)	(23.8m)	(32.7m)
Long-term Borrowings						(30.0m)	(30.0m)	(30.0m)
Cash From Financing Activities	(3.5m)	(15.3m)	1.6m	2.2m	(26.2m)	(29.2m)	(29.8m)	(27.4m)	725.0k	3.4m	2.7m	4.6m
Free Cash Flow	3.1m	23.3m	22.7m	14.6m	40.3m	69.9m	38.1m	74.1m	23.8m	33.8m	660.0k	(15.2m)

Report incorrect company information

View Cambrex profile

Competitors

Healthcare - Public

Healthcare - Public

Healthcare - Public

Albany Molecular Research

Healthcare - Subsidiary

Compare competitors